Cytotoxic therapy with diphtheria toxin fusion proteins

Drugs of the Future

Volumn 35, Issue 10, 2010, Pages 823-831

  Woo, Jung Hee ^a   Frankel, A ^a   Neville Jr , D M ^b  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b Angimmune LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CD19 ANTIGEN; CD22 ANTIGEN; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; DIPHTHERIA TOXIN AGGREGATION REDUCING LINKER FUSION PROTEIN; DIPHTHERIA TOXIN EPIDERMAL GROWTH FACTOR 13 FUSION PROTEIN; DIPHTHERIA TOXIN EPIDERMAL GROWTH FACTOR FUSION PROTEIN; DIPHTHERIA TOXIN EPITHELIAL CELL ADHESION MOLECULE 23 FUSION PROTEIN; DIPHTHERIA TOXIN GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR FUSION PROTEIN; DIPHTHERIA TOXIN INTERLEUKIN 3 FUSION PROTEIN; DIPHTHERIA TOXOID CRM197; HYBRID PROTEIN; IMMUNOTOXIN; LYSINE; RITUXIMAB; STEROID; TERBUTALINE; THALIDOMIDE; THEOPHYLLINE; TRANSFERRIN MUTANT DIPHTHERIA TOXIN FUSION PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANOREXIA; ANTIBODY TITER; ARTHRALGIA; ARTHRITIS; ASTHENIA; B CELL LYMPHOMA; BACKACHE; BLADDER CANCER; BRAIN EDEMA; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER PATIENT; CAPILLARY LEAK SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CHO CELL; CHRONIC LYMPHATIC LEUKEMIA; CONGESTIVE HEART FAILURE; CORYNEBACTERIUM DIPHTHERIAE; CUTANEOUS T CELL LYMPHOMA; CYTOTOXICITY; DAUDI CELL; DISEASE SEVERITY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; EDEMA; ESCHERICHIA COLI; FATIGUE; FEVER; FLU LIKE SYNDROME; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOGENICITY; KIDNEY INJURY; KUPFFER CELL; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER INJURY; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUDE RAT; OPPORTUNISTIC INFECTION; PAIN; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PSORIASIS; REVIEW; SEIZURE; SEZARY SYNDROME; SIDE EFFECT; SKIN MANIFESTATION; SQUIRREL; T CELL DEPLETION; THORAX PAIN; THROMBOCYTOPENIA; TRANSGENIC ANIMAL; TREATMENT DURATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS REACTIVATION; VOMITING; WILD TYPE; XENOGRAFT;

EID: 79956215035     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.010.1534010     Document Type: Review

References (101)

1. Choe, S., Bennett, M.J., Fujii, G., Curmi, P.M., Kantardjieff, K.A., Collier, R.J., Eisenberg, D. The crystal structure of diphtheria toxin. Nature 1992, 357(6375): 216-22.
2. Tsuneoka, M., Nakayama, K., Hatsuzawa, K., Komada, M., Kitamura, N., Mekada, E. Evidence for involvement of furin in cleavage and activation of diphtheria toxin. J Biol Chem 1993, 268(35): 26461-5.
3. Gordon, V.M., Klimpel, K.R., Arora, N., Henderson, M.A., Leppla, S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 1995, 63(1): 82-7.
4. Neville, D.M., Scharff, J., Srinivasachar, K. Anti-T cell immunotoxins: A look at post-endocytotic receptor-mediated routing. J Control Release 1993, 24(1-3): 133-44.
5. London, E. Diphtheria toxin: Membrane interaction and membrane translocation. Biochim Biophys Acta 1992, 1113(1): 25-51.
6. Donovan, J.J., Simon, M.I., Draper, R.K., Montal, M. Diphtheria toxin forms transmembrane channels in planar lipid bilayers. Proc Natl Acad Sci U S A 1981, 78(1): 172-6.
7. Kagan, B.L., Finkelstein, A., Colombini, M. Diphtheria toxin fragment forms large pores in phospholipid bilayer membranes. Proc Natl Acad Sci U S A 1981, 78(8): 4950-4.
8. Wiedlocha, A., Madshus, I.H., Mach, H., Middaugh, C.R., Olsnes, S. Tight folding of acidic fibroblast growth factor prevents its translocation to the cytosol with diphtheria toxin as vector. EMBO J 1992, 11(13): 4835-42.
9. Falnes, P.O., Choe, S., Madshus, I.H., Wilson, B.A., Olsnes, S. Inhibition of membrane translocation of diphtheria toxin A-fragment by internal disulfide bridges. J Biol Chem 1994, 269(11): 8402-7.
10. Ren, J., Kachel, K., Kim, H., Malenbaum, S.E., Collier, R.J., London, E. Interaction of diphtheria toxin T domain with molten globule-like proteins and its implications for translocation. Science 1999, 284(5416): 955-7.
11. Ratts, R., Zeng, H., Berg, E.A. et al. The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex. J Cell Biol 2003, 160(7): 1139-50.
12. Van Ness, B.G., Howard, J.B., Bodley, J.W. ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosylamino acid and its hydrolysis products. J Biol Chem 1980, 255(22): 10717-20.
13. Yamaizumi, M., Mekada, E., Uchida, T., Okada, Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978, 15(1): 245-50.
14. Thompson, J., Stavrou, S., Weetall, M. et al. Improved binding of a bivalent single-chain immunotoxin results in increased efficacy for in vivo T-cell depletion. Protein Eng 2001, 14(12): 1035-41.
15. Kim, G.B., Wang, Z., Liu, Y.Y. et al. A fold-back single-chain diabody format enhances the bioactivity of an anti-monkey CD3 recombinant diphtheria toxin-based immunotoxin. Protein Eng Des Sel 2007, 20(9): 425-32.
16. Woo, J.H., Liu, Y.Y., Mathias, A., Stavrou, S., Wang, Z., Thompson, J., Neville, D.M. Jr. Gene optimization is necessary to express a bivalent antihuman anti-T cell immunotoxin in Pichia pastoris. Protein Expr Purif 2002, 25(2): 270-82.
17. Liu, Y.Y., Gordienko, I., Mathias, A., Ma, S., Thompson, J., Woo, J.H., Neville, D.M. Jr. Expression of an anti-CD3 single-chain immunotoxin with a truncated diphtheria toxin in a mutant CHO cell line. Protein Expr Purif 2000, 19(2): 304-11.
18. Liu, Y.Y., Woo, J.H., Neville, D.M. Targeted introduction of a diphtheria toxin resistant mutation into the chromosomal EF-2 locus of Pichia pastoris and expression of immunotoxin in the EF-2 mutants. Protein Expr Purif 2003, 30(2): 262-74.
19. Woo, J.H., Liu, Y.Y., Stavrou, S., Neville, D.M. Jr. Increasing secretion of a bivalent anti-T-cell immunotoxin by Pichia pastoris. Appl Environ Microbiol 2004, 70(6): 3370-6.
20. Woo, J.H., Liu, Y.Y., Neville, D.M. Jr. Minimization of aggregation of secreted bivalent anti-human T cell immunotoxin in Pichia pastoris bioreactor culture by optimizing culture conditions for protein secretion. J Biotechnol 2006, 121(1): 75-85.
21. Woo, J.H., Neville, D.M. Jr. Separation of bivalent anti-T cell immunotoxin from Pichia pastoris glycoproteins by borate anion exchange. Biotechniques 2003, 35(2): 392-8.
22. Vallera, D.A., Chen, H., Sicheneder, A.R., Panoskaltsis-Mortari, A., Taras, E.P. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res 2009, 33(9): 1233-42.
23. Oh, S., Ohlfest, J.R., Todhunter, D.A., Vallera, V.D., Hall, W.A., Chen, H., Vallera, D.A. Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery. J Neurooncol 2009, 95(3): 331-42.
24. Stish, B.J., Chen, H., Shu, Y., Panoskaltsis-Mortari, A., Vallera, D.A. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv. Clin Cancer Res 2007, 13(10): 3058-67.
25. Todhunter, D.A., Hall, W.A., Rustamzadeh, E., Shu, Y., Doumbia, S.O., Vallera, D.A. A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model. Protein Eng Des Sel 2004, 17(2): 157-64.
26. Bacha, P., Williams, D.P., Waters, C., Williams, J.M., Murphy, J.R., Strom, T.B. Interleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J Exp Med 1988, 167(2): 612-22.
27. LeMaistre, C.F., Saleh, M.N., Kuzel, T.M. et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998, 91(2): 399-405.
28. Olsen, E., Duvic, M., Frankel, A. et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001, 19(2): 376-88.
29. Prince, H.M., Duvic, M., Martin, A. et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010, 28(11): 1870-7.
30. Rasku, M.A., Clem, A.L., Telang, S. et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008, 6: 12.
31. Dang, N.H., Pro, B., Hagemeister, F.B. et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br J Haematol 2007, 136(3): 439-47.
32. Woo, J.H., Liu, J.S., Kang, S.H. et al. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials. Protein Expr Purif 2008, 58(1): 1-11.
33. Neville, D.M. Jr., Scharff, J., Srinivasachar, K. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3. Proc Natl Acad Sci U S A 1992, 89(7): 2585-9.
34. Hu, H., Stavrou, S., Cairns Baker, B., Tornatore, C., Scharff, J., Okunieff, P., Neville, D.M. Jr. Depletion of T lymphocytes with immunotoxin retards the progress of experimental allergic encephalomyelitis in rhesus monkeys. Cell Immunol 1997, 177(1): 26-34.
35. Woo, J.H., Bour, S.H., Dang, T. et al. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). Cancer Immunol Immunother 2008, 57(8): 1225-39.
36. Frankel, A.E., Zuckero, S.L., Mankin, A.A. et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Curr Drug Targets 2009, 10(2): 104-9.
37. Urieto, J.O., Liu, T., Black, J.H. et al. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expr Purif 2004, 33(1): 123-33.
38. Frankel, A.E., McCubrey, J.A., Miller, M.S. et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000, 14(4): 576-85.
39. Alexander, R.L., Kucera, G.L., Klein, B., Frankel, A.E. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Bioconjug Chem 2000, 11(4): 564-8.
40. Alexander, R.L., Ramage, J., Kucera, G.L., Caligiuri, M.A., Frankel, A.E. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 2001, 25(10): 875-81.
41. Feuring-Buske, M., Frankel, A.E., Alexander, R.L., Gerhard, B., Hogge, D.E. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 2002, 62(6): 1730-6.
42. Black, J.H., McCubrey, J.A., Willingham, M.C., Ramage, J., Hogge, D.E., Frankel, A.E. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 2003, 17(1): 155-9.
43. Yalcintepe, L., Frankel, A.E., Hogge, D.E. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 2006, 108(10): 3530-7.
44. Cohen, K.A., Liu, T.F., Cline, J.M., Wagner, J.D., Hall, P.D., Frankel, A.E. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother 2005, 54(8): 799-806.
45. Frankel, A., Liu, J.S., Rizzieri, D., Hogge, D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma 2008, 49(3): 543-53.
46. Liu, T.F., Urieto, J.O., Moore, J.E., Miller, M.S., Lowe, A.C., Thorburn, A., Frankel, A.E. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol 2004, 32(3): 277-81.
47. Testa, U., Riccioni, R., Biffoni, M., Diverio, D., Lo-Coco, F., Foa, R., Peschle, C., Frankel, A.E. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood 2005, 106(7): 2527-9.
48. Hogge, D.E., Yalcintepe, L., Wong, S.H., Gerhard, B., Frankel, A.E. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 2006, 12(4): 1284-91.
49. Su, Y., Li, S.Y., Ghosh, S., Ortiz, J., Hogge, D.E., Frankel, A.E. Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials. Biologicals 2010, 38(1): 144-9.
50. Greenfield, L., Johnson, V.G., Youle, R.J. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987, 238(4826): 536-9.
51. Martell, L.A., Agrawal, A., Ross, D.A., Muraszko, K.M. Efficacy of transferrin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 1993, 53(6): 1348-53.
52. Laske, D.W., Ilercil, O., Akbasak, A., Youle, R.J., Oldfield, E.H. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 1994, 80(3): 520-6.
53. Engebraaten, O., Hjortland, G.O., Juell, S., Hirschberg, H., Fodstad, O. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 2002, 97(6): 846-52.
54. Johnson, V.G., Wrobel, C., Wilson, D., Zovickian, J., Greenfield, L., Oldfield, E.H., Youle, R. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 1989, 70(2): 240-8.
55. Laske, D.W., Youle, R.J., Oldfield, E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997, 3(12): 1362-8.
56. Jefferies, W.A., Brandon, M.R., Hunt, S.V., Williams, A.F., Gatter, K.C., Mason, D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312(5990): 162-3.
57. Weaver, M., Laske, D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003, 65(1): 3-13.
58. 389EGF in patients with solid malignancies that express EGF receptors (EGFr). Proc Am Soc Clin Oncol (ASCO) 1995, 14: Abst 1561.
59. Cohen, K.A., Liu, T., Bissonette, R., Puri, R.K., Frankel, A.E. DAB389EGF fusion protein therapy of refractory glioblastoma multiforme. Curr Pharm Biotechnol 2003, 4(1): 39-49.
60. Shaw, J.P., Akiyoshi, D.E., Arrigo, D.A. et al. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J Biol Chem 1991, 266(31): 21118-24.
61. Neal, D.E., Sharples, L., Smith, K., Fennelly, J., Hall, R.R., Harris, A.L. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990, 65(7): 1619-25.
62. Shinojima, N., Tada, K., Shiraishi, S. et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003, 63(20): 6962-70.
63. Liu, T.F., Cohen, K.A., Ramage, J.G., Willingham, M.C., Thorburn, A.M., Frankel, A.E. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res 2003, 63(8): 1834-7.
64. Liu, T.F., Hall, P.D., Cohen, K.A., Willingham, M.C., Cai, J., Thorburn, A., Frankel, A.E. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 2005, 11(1): 329-34.
65. Frankel, A.E., Ramage, J., Latimer, A. et al. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials. Protein Expr Purif 1999, 16(1): 190-201.
66. Frankel, A.E., Hall, P.D., Burbage, C., Vesely, J., Willingham, M., Bhalla, K., Kreitman, R.J. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood 1997, 90(9): 3654-61.
67. Hogge, D.E., Willman, C.L., Kreitman, R.J. et al. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein. Blood 1998, 92(2): 589-95.
68. Feuring-Buske, M., Frankel, A., Gerhard, B., Hogge, D. Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells. Exp Hematol 2000, 28(12): 1390-400.
69. Frankel, A.E., Lilly, M., Kreitman, R. et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood 1998, 92(11): 4279-86.
70. Hall, P.D., Willingham, M.C., Kreitman, R.J., Frankel, A.E. DT388-GMCSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte-macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia. Leukemia 1999, 13(4): 629-33.
71. Hall, P.D., Kreitman, R.J., Willingham, M.C., Frankel, A.E. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicol Appl Pharmacol 1998, 150(1): 91-7.
72. Hotchkiss, C.E., Hall, P.D., Cline, J.M. et al. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor, in cynomolgus monkeys. Toxicol Appl Pharmacol 1999, 158(2): 152-60.
73. Frankel, A.E., Powell, B.L., Hall, P.D., Case, L.D., Kreitman, R.J. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002, 8(5): 1004-13.
74. Abi-Habib, R.J., Liu, S., Bugge, T.H., Leppla, S.H., Frankel, A.E. A urokinase- activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood 2004, 104(7): 2143-8.
75. Westcott, M.M., Abi-Habib, R.J., Cohen, K.A. et al. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther 2004, 3(12): 1681-9.
76. Foss, F.M., Bacha, P., Osann, K.E., Demierre, M.F., Bell, T., Kuzel, T. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: Decreased frequency and severity with steroid premedication. Clin Lymphoma 2001, 1(4): 298-302.
77. Baluna, R., Rizo, J., Gordon, B.E., Ghetie, V., Vitetta, E.S. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci U S A 1999, 96(7): 3957-62.
78. Androne, A.S., Hryniewicz, K., Hudaihed, A., Mancini, D., Lamanca, J., Katz, S.D. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 2004, 93(10): 1254-9.
79. Avarbock, A.B., Loren, A.W., Park, J.Y., Junkins-Hopkins, J.M., Choi, J., Litzky, L.A., Rook, A.H. Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosis. Am J Hematol 2008, 83(7): 593-5.
80. Kinoshita, Y., Kasaoka, S., Fujita, M., Oshima, C., Kawamura, Y., Tsuruta, R., Maekawa, T. Synchronized changes in serum vascular endothelial growth factor during the clinical course of chronic systemic capillary leak syndrome. Intern Med 2010, 49(8): 791-4.
81. Droder, R.M., Kyle, R.A., Greipp, P.R. Control of systemic capillary leak syndrome with aminophylline and terbutaline. Am J Med 1992, 92(5): 523-6.
82. Staak, J.O., Glossmann, J.P., Esser, J.M., Diehl, V., Mietz, H., Josting, A. Thalidomide for systemic capillary leak syndrome. Am J Med 2003, 115(4): 332-4.
83. Lambert, M., Launay, D., Hachulla, E. et al. High-dose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Crit Care Med 2008, 36(7): 2184-7.
84. Hall, P.D., Razzouk, B.I., Willoughby, T.E., McLean, T.W., Frankel, A.E. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity. J Pediatr Hematol Oncol 2002, 24(7): 521-6.
85. Davis, C.G., Datta, D., baker, M.P., Keen, S., Rust, A.J. (Angelica TheraPeutics, Inc.). Modified toxins. WO 2009110944.
86. Thompson, J., Hu, H., Scharff, J., Neville, D.M. Jr. An anti-CD3 singlechain immunotoxin with a truncated diphtheria toxin avoids inhibition by pre-existing antibodies in human blood. J Biol Chem 1995, 270(47): 28037-28041.
87. Kageyama, T., Ohishi, M., Miyamoto, S., Mizushima, H., Iwamoto, R., Mekada, E. Diphtheria toxin mutant CRM197 possesses weak EF2-ADP-ribosyl activity that potentiates its anti-tumorigenic activity. J Biochem 2007, 142(1): 95-104.
88. Ho, V.T., Zahrieh, D., Hochberg, E. et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104(4): 1224-6.
89. Shaughnessy, P.J., Bachier, C., Grimley, M. et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2005, 11(3): 188-93.
90. Frankel, A.E., Fleming, D.R., Hall, P.D., Powell, B.L., Black, J.H., Leftwich, C., Gartenhaus, R. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res 2003, 9(10, Pt. 1): 3555-61.
91. Morgan, S.J., Seymour, J.F., Prince, H.M., Westerman, D.A., Wolf, M.M. Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression. Clin Cancer Res 2004, 10(10): 3572-5.
92. Frankel, A.E., Surendranathan, A., Black, J.H., White, A., Ganjoo, K., Cripe, L.D. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 2006, 106(10): 2158-64.
93. Bagel, J., Garland, W.T., Breneman, D. et al. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial. J Am Acad Dermatol 1998, 38(6, Pt. 1): 938-44.
94. Foss, F., Demierre, M.F., DiVenuti, G. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106(2): 454-7.
95. Dang, N.H., Hagemeister, F.B., Pro, B. et al. Phase II study of denileukin diftitox for relapsed/refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2004, 22(20): 4095-102.
96. Dang, N.H., Fayad, L., McLaughlin, P. et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non- Hodgkin lymphoma. Br J Haematol 2007, 138(4): 502-5.
97. Kuzel, T.M., Li, S., Eklund, J. et al. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497. Leuk Lymphoma 2007, 48(12): 2397-402.
98. Gerena-Lewis, M., Crawford, J., Bonomi, P. et al. A phase II trial of denileukin diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol 2009, 32(3): 269-73.
99. LeMaistre, C.F., Meneghetti, C., Rosenblum, M. et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992, 79(10): 2547-54.
100. Tepler, I., Schwartz, G., Parker, K., Charette, J., Kadin, M.E., Woodworth, T.G., Schnipper, L.E. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: Complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 1994, 73(4): 1276-85.
101. Hesketh, P., Caguioa, P., Koh, H. et al. Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 1993, 11(9): 1682-90.